Assistant U.S. Attorney Roger Stefin claimed some of Melgen's patients developed serious eye infections from unnecessary Lucentis injections administered on the basis of bogus macular degeneration ...

The need for frequent injections with Lucentis and other wet AMD therapies " leaves many people under-treated and susceptible to vision loss," according to Levi Garraway, Roche's chief medical ...

Each month for 2 years Verle received an injection directly into his eye—and miraculously his ... The really striking finding in both the Lucentis trials was that about 35 and 40 percent of ...

that gives patients an alternative to regular injections into the eye. Susvimo has the same active ingredient as Roche's big-selling therapy Lucentis (ranibizumab), a VEGF inhibitor administered ...

He pointed out that frequent anti-VEGF injections into the eye can be a significant burden ... "For example, in one trial, while ranibizumab [Lucentis] treatment resulted in a mean gain of ...

The drug, which is given by injection into the eye, was generally well tolerated in clinical studies, Novartis said. Lucentis was developed by Roche Holding AG (ROG.VX) unit Genentech, which holds ...